Skip to main content
. 2023 Jun 28;15(13):3397. doi: 10.3390/cancers15133397

Figure 4.

Figure 4

Overall survival of metastatic breast cancer patients according to the (A) number of circulating tumor cells (CTCs), (B) number of megakaryocytes 0 vs. ≥1, (C) low vs. high systemic immune-inflammation index (SII), (D) low vs. high pan-immune-inflammation value (PIV), (E) low vs. high relative changes in SII (ΔSII%), and (F) low vs. high relative changes in PIV (ΔPIV%).